Free Newsletter
New vaccine/chemo combo effective in cancer study
New trial data shows that the combination of a chemotherapy drug and a new vaccine significantly prolonged the survival of patients with glioblastoma, the aggressive brain cancer that now afflicts Senator Ted Kennedy. The therapy is the brainchild of Houston neurosurgeon Samuel Hassenbusch, who became the first of 23 patients to enroll in the study after he was diagnosed with the disease. He died earlier this year.
In a surprise, the researchers found that the chemotherapy did not interfere with the vaccine. In fact, the chemotherapy evidently enhanced the vaccine's effect.
"I'm biased, but this is some of the best data we've ever seen," Duke University neurosurgean Dr. John Sampson told the Houston Chronicle. "It appears very promising for a cancer where there's been little hope."
- read the article in the Houston Chronicle
Related Article:
Kennedy's best hope may lie in cancer vaccine trial
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceVaccines email newsletter for FREE!
Be the first to comment